Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

NEW YORK, Aug 13 (Reuters) - Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

STOXX 600 marks fifth week of gains Pfizer COVID-19 pill turbo-charges travel stocks Allegro surges after Mall Group deal German, French stocks scale new peaks Nov 5 (Reuters) - European equities ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...

Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...

Pfizer's >7% dividend yield is attractive, but faces significant risk due to political, regulatory, and business headwinds impacting revenue and profitability. Major threats include U.S. healthcare ...

Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a ...

Pfizer stock is a deep-value kind of blue chip with a yield of more than 7%. The dividend looks safe — for now. The real question is whether there’s enough growth and innovation in the pipeline as the ...